Prevalence and co-prevalence of comorbidities among Chinese adult patients with type 2 diabetes mellitus: a cross-sectional, multicenter, retrospective, observational study based on 3B study database

被引:6
作者
Ji, Qiuhe [1 ]
Chai, Shangyu [2 ]
Zhang, Ruya [2 ]
Li, Jihu [3 ]
Zheng, Yiman [2 ]
Rajpathak, Swapnil [4 ]
机构
[1] Xian Int Med Ctr Hosp, Dept Endocrinol & Metab, Xian, Shanxi, Peoples R China
[2] Merck Sharp & Dohme MSD China, Value & Implementat Global Med & Sci Affairs, Shanghai, Peoples R China
[3] Merck Sharp & Dohme MSD China, Govt Affairs & Market Access, Shanghai, Peoples R China
[4] Merck & Co Inc, Merck Res Labs, Value & Implementat Outcomes Res, Rahway, NJ USA
关键词
type; 2; diabetes; comorbidity; prevalence; co-prevalence; 3B study; CARDIOVASCULAR-DISEASES; RISK-FACTORS; MANAGEMENT; HYPERTENSION; POPULATION; STATEMENT; MORTALITY; OBESITY;
D O I
10.3389/fendo.2024.1362433
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: This study aimed to investigate the prevalence and co-prevalence of comorbidities among Chinese individuals with type 2 diabetes (T2DM). Methods: Medical records were retrospectively retrieved from the 3B Study database, which provided a comprehensive assessment of comorbid conditions in Chinese adult outpatients with T2DM. Patient characteristics, laboratory measures, and comorbidities were summarized via descriptive analyses, overall and by subgroups of age (<65, 65-74, 75 years) and gender. Results: Among 25,454 eligible patients, 53% were female, and the median age was 63 years. The median time of diabetes duration was 6.18 years. A total of 20,309 (79.8%) patients had at least one comorbid condition alongside T2DM. The prevalence of patients with one, two, three, and four or more comorbid conditions was 28.0%, 24.6%, 15.6%, and 11.6%, respectively. Comorbidity burden increased with longer T2DM duration. Older age groups also exhibited higher comorbidity burden. Females with T2DM had a higher overall percentage of comorbidities compared to males (42.7% vs. 37.1%). The most common comorbid conditions in T2DM patients were hypertension (HTN) in 59.9%, overweight/obesity in 58.3%, hyperlipidemia in 42.0%, retinopathy in 16.5%, neuropathy in 15.2%, cardiovascular disease (CVD) in 14.9%, and renal disease in 14.4%. The highest co-prevalence was observed for overweight/obesity and HTN (37.6%), followed by HTN and hyperlipidemia (29.8%), overweight/obesity and hyperlipidemia (27.3%), HTN and CVD (12.6%), HTN and retinopathy (12.1%), and HTN and renal disease (11.3%). Conclusion: The majority of T2DM patients exhibit multiple comorbidities. Considering the presence of multimorbidity is crucial in clinical decision-making. Systematic review registration https://clinicaltrials.gov/, identifier NCT01128205.
引用
收藏
页数:16
相关论文
共 52 条
[1]   2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension [J].
Afridi, I ;
Canny, J ;
Yao, CH ;
Christensen, B ;
Cooper, RS ;
Kadiri, S ;
Hill, S ;
Kaplan, N ;
Kuschnir, E ;
Lexchin, J ;
Mendis, S ;
Poulter, N ;
Psaty, BM ;
Rahn, KH ;
Sheps, SG ;
Whitworth, J ;
Yach, D ;
Bengoa, R ;
Ramsay, L ;
Kaplan, N ;
Mendis, S ;
Poulter, N ;
Whitworth, J .
JOURNAL OF HYPERTENSION, 2003, 21 (11) :1983-1992
[2]   Prevalence of comorbidities in patients with type-2 diabetes mellitus [J].
Akin, Seydahmet ;
Boluk, Cem .
PRIMARY CARE DIABETES, 2020, 14 (05) :431-434
[3]   Association between different types of comorbidity and disease burden in patients with diabetes [J].
An, JaeJin ;
Le, Quang A. ;
Dang, Tracy .
JOURNAL OF DIABETES, 2019, 11 (01) :65-74
[4]  
[Anonymous], 2017, Lancet, V389, pe1, DOI [10.1016/S0140-6736(16)32607-1, 10.1016/S0140-6736(16)32609-5, 10.1016/S0140-6736(16)32632-0, 10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)32606-X, 10.1016/S0140-6736(16)32610-1, 10.1016/S0140-6736(16)32608-3, 10.1016/S0140-6736(16)32605-8]
[5]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[6]  
[Anonymous], 2019, U.S
[7]   Obesity in Older Type 2 Diabetic Patients: Does Working Environment Add Vulnerability? [J].
Brandao, Maria Piedade ;
Cardoso, Margarida Fonseca .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2018, 15 (12)
[8]   SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications [J].
Brown, Emily ;
Heerspink, Hiddo J. L. ;
Cuthbertson, Daniel J. ;
Wilding, John P. H. .
LANCET, 2021, 398 (10296) :262-276
[9]  
Chen Chunming, 2004, Biomed Environ Sci, V17 Suppl, P1
[10]  
Chen-Xiao S, 2018, Chin Gen Pract, V21, P1785